Page 33 - Dwight Egan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article SALT LAKE CITY, Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14. Dr. Gottlieb is the former Food and Drug Administration (FDA) Commissioner and former Centers for Medicare & Medicaid Services (CMS) S...

Share this article SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is anticipated to be the highest in the Company's history and to surpass analyst estimates. Analysts' estimates for the fourth quarter ranged from $24 million to $25.98 million. Quarterly revenue is anticipated to exceed the h...

Share this article SALT LAKE CITY, Dec. 22, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01.  The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain began Sunday ...

Share: SALT LAKE CITY, Dec. 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has sold over 10 million of its Logix Smart™ COVID-19 Test Kits to its domestic and international network of laboratories, hospitals, and distributors. In conjunction with this milestone, the Company has also announced strong revenue in Q4 anticipated to exceed that of Q3 In conjunction with this milestone, the Company has also announced strong rev...